logo
Share SHARE
FONT-SIZE Plus   Neg

Merck KGaA Says NICE Issues Positive FAD Recommending Routine NHS Use Of Erbitux

Merck KGaA (MKGAY.PK) announced that the National Institute for Health and Care Excellence or NICE for England has issued a positive Final Appraisal Determination or FAD recommending the routine National Health Service (NHS) use of Erbitux (cetuximab) in combination with platinum-based chemotherapy as a first-line therapy for the treatment of patients with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity.

NICE's decision confirmed the positive benefit Erbitux can have on the survival of patients in this setting. Erbitux is already established and reimbursed as an effective therapy for different stages of SCCHN across many countries worldwide.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Cable-cutters have now one more reason to do so as live television streaming will be available on YouTube TV in 14 more markets in the U.S. Facebook Chief Operating Officer Sheryl Sandberg has donated nearly $100 million in Facebook shares to charity. This is her second charitable donation within a year. A document was filed on Thursday with the Security and Exchange Commission, which shows that Sandberg transferred shares to a special fund she uses for charitable donations. Ford Motor Co.'s new CEO Jim Hackett has taken a more cautious approach to the automaker's plans for rolling out autonomous vehicles. Ford is currently undertaking a 100-day review of its operations and Hackett indicated at delays to the company's plans to launch a fully-autonomous vehicle by 2021.
comments powered by Disqus
Follow RTT